Company news
Vcanbio Cell & Gene Engineering Corp., Ltd. news in 2026
Vcanbio Cell & Gene Engineering Corp., Ltd.'s news releases, calls and decks from 2026, newest first.
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Report for Q3 2026
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Resolutions of the 4th Extraordinary Meeting of the 12th Board of Directors
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Re-appointment of Accounting Firm
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
October 28, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2026
October 22, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Resolutions of the 3rd Extraordinary Meeting of the 12th Board of Directors
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Extension of the Raised Funds Investment Project "Development of Tumor Marker Diagnostic Reagents"
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Change of Certain Raised Funds Investment Projects and Implementation of Raised Funds Investment Projects via Providing Loans to Controlled Subsidiary with Raised Funds
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Change of Business Scope and Amendment to the Articles of Association
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Redemption upon Maturity of Cash Management Products Purchased with Idle Raised Funds
October 8, 2026
Announcement on Measures in the Form of Warning Letters Received by the Company and Relevant Persons
September 15, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing
August 27, 2026
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 30, 2026
Announcement on Progress in Wholly-owned Subsidiary's Clinical Trial for VUM02 Injection
July 17, 2026
Announcement on Progress in Redemption of Temporarily Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
July 1, 2026
Announcement on Convening the 2025 Annual Performance Briefing
June 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 18, 2026
Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
May 15, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
May 12, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 24, 2026
Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
April 21, 2026
Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management
April 1, 2026
Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Maturity
March 31, 2026
Announcement on Subsidiary’s Receipt of a Medical Device Registration Certificate
March 1, 2026